Search

Your search keyword '"Addonizio L"' showing total 187 results
Start Over Author "Addonizio L"
187 results on '"Addonizio L"'

15. Pediatric heart transplantation across a positive crossmatch: First year results from the CTOTC-04 multi-institutional study

Author

Webber, S., primary, Zeevi, A., additional, Mason, K., additional, Addonizio, L., additional, Blume, E., additional, Dipchand, A., additional, Shaddy, R., additional, Feingold, B., additional, Canter, C., additional, Hsu, D., additional, Mahle, W., additional, Armstrong, B., additional, Morrison, Y., additional, Ikle, D., additional, Diop, H., additional, and Odim, J., additional

Published
2018
Full Text
View/download PDF

16. Pediatric Heart Transplantation: Transitioning to Adult Care

Author

Pahl, E., primary, Van't Hof, K., additional, Andrei, A., additional, Shankel, T., additional, Chinnock, R., additional, Miyamoto, S., additional, Ambardekar, A., additional, Addonizio, L., additional, Latif, F., additional, Lefkowitz, D., additional, Goldberg, L., additional, Hollander, S., additional, Pham, M., additional, and Grady, K., additional

Published
2017
Full Text
View/download PDF

18. Prevalence of Polyreactive Innate-Like B Cells Among Graft-Infiltrating B Cells in Human Cardiac Allograft Vasculopathy

Author

Chatterjee, D., primary, Moore, C., additional, Gao, B., additional, Clerkin, K.J., additional, See, S.B., additional, Shaked, D., additional, Rogers, K.J., additional, Nunez, S., additional, Veras, Y., additional, Addonizio, L., additional, Givertz, M.M., additional, Naka, Y., additional, Mancini, D., additional, Vasilescu, R., additional, Marboe, C., additional, Restaino, S., additional, Madsen, J.C., additional, and Zorn, E., additional

Published
2016
Full Text
View/download PDF

26. The Influence of Race and Common Genetic Variations on Outcomes After Pediatric Heart Transplantation

Author

Green, D. J., Brooks, M. M., Burckart, G. J., Chinnock, R. E., Canter, C., Addonizio, L. J., Bernstein, D., Kirklin, J. K., Naftel, D. C., Girnita, D. M., Zeevi, A., and Webber, S. A.

Abstract

Significant racial disparity remains in the incidence of unfavorable outcomes following heart transplantation. We sought to determine which pediatric posttransplantation outcomes differ by race and whether these can be explained by recipient demographic, clinical, and genetic attributes. Data were collected for 80 black and 450 nonblack pediatric recipients transplanted at 1 of 6 centers between 1993 and 2008. Genotyping was performed for 20 candidate genes. Average follow‐up was 6.25 years. Unadjusted 5‐year rates for death (p = 0.001), graft loss (p = 0.015), acute rejection with severe hemodynamic compromise (p = 0.001), late rejection (p = 0.005), and late rejection with hemodynamic compromise (p = 0.004) were significantly higher among blacks compared with nonblacks. Black recipients were more likely to be older at the time of transplantation (p < 0.001), suffer from cardiomyopathy (p = 0.004), and have public insurance (p < 0.001), and were less likely to undergo induction therapy (p = 0.0039). In multivariate regression models adjusting for age, sex, cardiac diagnosis, insurance status, and genetic variations, black race remained a significant risk factor for all the above outcomes. These clinical and genetic variables explained only 8–19% of the excess risk observed for black recipients. We have confirmed racial differences in survival, graft loss, and several rejection outcomes following heart transplantation in children, which could not be fully explained by differences in recipient attributes. Significant racial differences persist in pediatric heart transplant outcomes and can only be partly explained by common genetic variations.

Published
2017
Full Text
View/download PDF

29. NEW ONSET GRAFT DYSFUNCTION AFTER HEART TRANSPLANTATION - INCIDENCE AND MECHANISM-RELATED IN-HOSPITAL OUTCOMES

Author

Shahzad, K., primary, Aziz, Q. A., additional, Cadeiras, M., additional, Leva, J., additional, Ho, E. K., additional, Vlad, G., additional, Vasilescu, E. R., additional, Latif, F., additional, Sinha, A., additional, Burke, E., additional, Addonizio, L. J., additional, Marboe, C. C., additional, Suciu-Foca, N., additional, and Deng, M. C., additional

Published
2010
Full Text
View/download PDF

32. 532: Genetic Polymorphisms Impact the Risk of Infection in Pediatric Heart Transplantation – A Multi-Center Study

Author

Girnita, D.M., primary, Brooks, M.M., additional, Webber, S.A., additional, Burckart, G.J., additional, Ferrell, R., additional, Girnita, A.L., additional, Chinnock, R., additional, Canter, C., additional, Addonizio, L., additional, Bernstein, D., additional, Kirklin, J.K., additional, Naftel, D., additional, and Zeevi, A., additional

Published
2009
Full Text
View/download PDF

33. 26-OR: Impact of genetic polymorphisms on rejection with hemodynamic compromise – A multi-institutional study

Author

Girnita, D.M., primary, Webber, S.A., additional, Brooks, M.M., additional, Burckart, G.J., additional, Ferrell, R., additional, Chinnock, R., additional, Canter, C., additional, Addonizio, L., additional, Bernstein, D., additional, Kirklin, J.K., additional, Naftel, D., additional, Girnita, A.L., additional, and Zeevi, A., additional

Published
2008
Full Text
View/download PDF

34. 314: Genotypic Variation and Phenotypic Characterization of Granzyme B Gene Polymorphisms

Author

Girnita, D.M., primary, Webber, S.A., additional, Ferrell, R., additional, Brooks, M.M., additional, DeCroo, S., additional, Burckart, G., additional, Zdanowicz, G., additional, Chinnock, R., additional, Canter, C., additional, Addonizio, L., additional, Bernstein, D., additional, Kirklin, J.K., additional, Naftel, D., additional, Smith, L., additional, Girnita, A.L., additional, and Zeevi, A., additional

Published
2008
Full Text
View/download PDF

35. 40-OR: The combination high VEGF/high IL-6 and low IL-10 gene polymorphism impact the risk of acute rejection in pediatric heart transplantation – a multicenter study

Author

Girnita, D.M., primary, Brooks, M., additional, Webber, S., additional, Burckart, G., additional, Ferrell, R., additional, Zdanowicz, G., additional, Chinnock, R., additional, Canter, C., additional, Addonizio, L., additional, Bernstein, D., additional, Kirklin, J., additional, Naftel, D., additional, Girnita, A., additional, and Zeevi, A., additional

Published
2007
Full Text
View/download PDF

42. ABH‐Glycan Microarray Characterizes ABOSubtype Antibodies: Fine Specificity of Immune Tolerance After ABO‐Incompatible Transplantation

Author

Jeyakanthan, M., Meloncelli, P. J., Zou, L., Lowary, T. L., Larsen, I., Maier, S., Tao, K., Rusch, J., Chinnock, R., Shaw, N., Burch, M., Beddows, K., Addonizio, L., Zuckerman, W., Pahl, E., Rutledge, J., Kanter, K. R., Cairo, C. W., Buriak, J. M., Ross, D., Rebeyka, I., and West, L. J.

Abstract

Organ transplantation from ABOblood group–incompatible (ABOi) donors requires accurate detection, effective removal and subsequent surveillance of antidonor antibodies. Because ABHantigen subtypes are expressed differently in various cells and organs, measurement of antibodies specific for the antigen subtypes in the graft is essential. Erythrocyte agglutination, the century‐old assay used clinically, does not discriminate subtype‐specific ABOantibodies and provides limited information on antibody isotypes. We designed and created an ABO‐glycan microarray and demonstrated the precise assessment of both the presence and, importantly, the absence of donor‐specific antibodies in an international study of pediatric heart transplant patients. Specific IgM, IgG, and IgA isotype antibodies to nonself ABHsubtypes were detected in control participants and recipients of ABO‐compatible transplants. Conversely, in children who received ABOi transplants, antibodies specific for A subtype IIand/or B subtype IIantigens—the only ABHantigen subtypes expressed in heart tissue—were absent, demonstrating the fine specificity of B cell tolerance to donor/graft blood group antigens. In contrast to the hemagglutination assay, the ABO‐glycan microarray allows detailed characterization of donor‐specific antibodies necessary for effective transplant management, representing a major step forward in precise ABOantibody detection. The authors design a novel ABH‐glycan microarray and demonstrate its effectiveness and accuracy in confirming donor‐specific B cell tolerance in a cohort of ABO‐incompatible pediatric heart transplant patients.

Published
2016
Full Text
View/download PDF

49. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study

Author

Webber, S.A., Naftel, D.C., Fricker, F.J., Olesnevich, P., Blume, E.D., Addonizio, L., Kirklin, J.K., and Canter, C.E.

Abstract

Background: Post-transplant lymphoproliferative disorders (PTLD) are an important cause of morbidity and mortality after organ transplantation. We sought to better define the prevalence, pathology, current therapeutic approaches, and outcomes of PTLD in a large group of children who had received heart transplants. Methods: We assessed data on patients followed up at 19 centres in the Pediatric Heart Transplant Study (PHTS) from 1993 to 2002. Probability of freedom from PTLD was assessed along with details of presentation, pathology, treatment, and outcomes. Risk factors for survival and event-free survival were investigated. Findings: Of 1184 primary transplant recipients, 56 (5%) developed PTLD. Probability of freedom from PTLD was 98% at 1 year, 94% at 3 years, and 92% at 5 years. Mean time to PTLD was 23.8 months. Most common sites of disease were gastrointestinal tract (n=22, 39%) and respiratory system (n=14, 25%). Histology was polymorphic in 35 (65%) and monomorphic in 19 (35%). 47 of 48 cases were of B-cell origin, 39 of 45 (87%) were Epstein-Barr virus positive. Probability of survival was 75% at 1 year, 68% at 3 years, and 67% at 5 years after diagnosis. Death from graft loss was as frequent as death from PTLD. Interpretation: About 5% of paediatric heart-transplant recipients develop PTLD, almost always of B-cell lineage and driven by Epstein-Barr virus. Although many achieve satisfactory outcomes, mortality remains substantial with death due to progressive disease and allograft loss. Advances in management should focus on strategies to protect the allograft as well as improved therapies for PTLD.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results